Product Portfolio
Enter at least 3 characters

HOME > Product Portfolio

The following list includes some of Chiesi's products that are available in the UK. Please visit http://www.medicines.org.uk/emc/ or https://www.emcmedicines.com/northernireland (NI) for more information.

 

Amryt Pharmaceuticals DAC is a wholly owned subsidiary of CHIESI SpA and the Marketing Authorisation Holder for (Myalepta/Lojuxta/Filsuvez) in the EU and UK.

 

For the UK: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.

 

For Ireland: Adverse events should be reported to HPRA Pharmacovigilance - www.hpra.ie.  Adverse events should also be reported to Chiesi Limited on 1800 817459 (IE) or PV.UK@Chiesi.com.

 

GB-CHI-2400008 June 2024 

 

Summaries of Product Characteristics (SPC) & Patient Information Leaflets (PIL)

SPC - Clenil® Modulite® 50mcg (with Dose Indicator)
SPC - Clenil® Modulite® 100mcg (with Dose Indicator)  
SPC - Clenil® Modulite® 200mcg (with Dose Indicator) 
SPC - Clenil® Modulite® 250mcg (with Dose Indicator)

PIL - Clenil® Modulite® 50mcg (with Dose Indicator)
PIL - Clenil® Modulite® 50mcg (without Dose Indicator)

PIL - Clenil® Modulite® 100mcg (with Dose Indicator)
PIL - Clenil® Modulite® 100mcg (without Dose Indicator)
PIL - Clenil® Modulite® 200mcg (with Dose Indicator)
PIL - Clenil® Modulite® 200mcg (without Dose Indicator)

PIL - Clenil® Modulite® 250mcg (with Dose Indicator)
PIL - Clenil® Modulite® 250mcg (without Dose Indicator)

SPC 

PIL 

SPC 

PIL 

SPC 

PIL 

SPC 

PIL

SPC 

PIL 

SPC 

PIL 

SPC
PIL 

SPC 

PIL 

SPC 

PIL

SPC 
PIL 

SPC 
PIL 

SPC 
PIL